Erhan GÖKMEN
Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalı
Research areas: Oncology, Health Sciences, Medicine, Internal Medicine Sciences, Internal Diseases, Hematology, Surgery Medicine Sciences, Life Sciences, Fundamental Medical Sciences, Pathology
Publications
- Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey (2026)
- DUSP29 does not regulate melanoma–myoblast interactions in a skeletal muscle co-culture model (2026)
- Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group (2026)
- Comparison of Tailor X and NSABP-20 regarding cost-effectiveness of recurrence score (RS®) for adjuvant chemotherapy decision in early-stage breast cancer (2026)
- Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use (2026)
- Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (2025)
- Real-World Pathologic Complete Response Rates with Neoadjuvant Pembrolizumab in Stage II–III Triple-Negative Breast Cancer: Impact of Ki-67 Proliferation Index (2025)
- Body Mass Index as an Independent Prognostic Factor in Second-Line Nivolumab Therapy for Metastatic Clear Cell Renal Cell Carcinoma (2025)
- Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety (2025)
- The Impact of the Hereditary Angioedema Attack Diary Mobile Application on Quality of Life and Treatment Adherence (2025)
- Skeletal muscle index as a prognostic biomarker for survival in HER2-positive and triple-negative breast cancer: a retrospective cohort study (2025)
- Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program (2025)
- Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data (2025)
- Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety (2025)
- Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab (2025)
- Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs (2025)
- Malignant transformations in mature cystic teratomas: A case report and literature review (2025)
- First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial (2025)
- HoLEP en los pacientes con y sin retención aguda de orina que precisa sondaje: resultados quirúrgicos y funcionales (2025)
- Impact of demographic parameters and drainage techniques on the prognosis of emphysematous pyelonephritis: A 10-year single-center retrospective study (2025)
- Real-World Outcomes of Adjuvant Paclitaxel and Trastuzumab Therapy in Lymph Node-Negative, HER2-Positive Early-Stage Breast Cancer: A Multicenter Retrospective Data Analysis (2025)
- The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer (2024)
- Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2024)
- Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma (2024)
- 185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07) (2024)
- A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) (2024)
- Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series (2024)
- Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 (2023)
- The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study (2023)
- Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial (2023)
- Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey (2023)
- Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization. (2023)
- Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial (2023)
- Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group (2023)
- Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (2023)
- Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023) (2023)
- 429P The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study (2023)
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. (2022)
- 164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355 (2022)
- Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre (2021)
- 124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey (2021)
- Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis (2021)
- Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre (2021)
- KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC (2021)
- Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer (2021)
- The prevalence and prognostic importance of the androgen receptor in triple-negative breast cancer (2021)
- Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience (2021)
- Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (2021)
- Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey. (2020)
- Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia (2020)
- Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri (2020)
- Ege Ünversitesi hastanesinde prostat kanserlerinin epdemyolojisi ve genel sağkalım özellkleri (2020)
- BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations (2020)
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020)
- Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (2020)
- Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri. (2020)
- Ege Üniversitesi Hastanesinde testis kanserlerinin epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege Üniversitesi Hastanesinde erkek genital sistem kanserlerinin epidemiyolojik ve genel sağkalım özellikleri (2019)
- Genotyping of DRD4 and DAT1 genes may differentiate symptoms of ADHD and sluggish cognitive tempo (2019)
- Ege Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege Üniversitesi Hastanesinde erkek genital sistem kanserlerinin epidemiyolojik ve genel sağ kalım özellikleri (2019)
- Ege Üniversitesi Hastanesi veri tabanındaki erkek genital sistem kanserlerinin epidemiyolojik ve genel sağkalım özellikleri. (2019)
- Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey (2019)
- Ege U¨niversitesi Hastanesinde testis kanserlerinin epidemiyolojisi ve genel sagˆ kalım o¨zellikleri (2019)
- Long-Term Follow-Up of Patients with Male Breast Cancer, Single-Center Experience (2019)
- Ege Üniversitesi Hastanesinde renal kanser hastalarının epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege Ü niversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege U¨niversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sagˆ kalım o¨zellikleri (2019)
- Ege Üniversitesi Hastanesinde testis kanserlerinin epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege U¨niversitesi Hastanesinde renal kanser hastalarının epidemiyolojisi ve genel sagˆ kalım o¨zellikleri (2019)
- Ege U¨niversitesi Hastanesinde erkek genital sistem kanserlerinin epidemiyolojik ve genel sagˆ kalım o¨zellikleri (2019)
- Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study (2019)
- Ege Üniversitesi Hastanesinde erkek genital sistem kanserlerinin epidemiyolojik ve genel sağkalım özellikleri (2019)
- DIMINISHED OVARIAN RESERVE IN A NEWLY DIAGNOSED BREAST CANCER PATIENT WITH HETEROZYGOTE ATAXIA TELENGIECTTASIA MUTATED (ATM) GENE MUTATION (2018)
- Diminished ovarian reserve in a newly diagnosed breast cancer patient with heterozygote Ataxia Telengiectasia mutated (ATM) gene mutation (2018)
- H. Onay, A.E. Solmaz, L. Yeniay, E. Gökmen, N. Özdemir, S. Alanyalı, A. Oktay, Z. Özsaran, M. Kapkaç, F. Özkınay. Meme kanserli 737 olguda brca1-brca2 mutasyon analizi sonuçlarımız: mutasyon dağılımımız ve 12 yeni mutasyon. Ulusal Kanser Kongresi 19-23 Nisan 2017. (2017)
- Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a middle-income country, Turkey: Results of a Prospective Multicenter Study (2017)
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (2017)
- Comparison of HER2 status determination methods in HER2 (2 +) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH) (2017)
- Areview of 20 year experience with prenatal diagnosis records 9297 cases from Turkey (2016)
- Comparison of Her2 status determination methods Fluorescent in situ hybridization FISH vs dual silver enhanced in situ hybridization SISH (2016)
- Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey (2016)
- Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey. (2016)
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2016)
- Results of the Turkish prospective multi-center study utilizing the 21-gene Oncotype DX assay: Decision impact analysis. (2015)
- The survival rate at 5 years in Turkish metastatic melanoma patients treated with ipilimumab: Final analysis of MIPI-TURK (2015)
- Mutation analysis of the BRCA1 and BRCA2 genes in Turkish patients with breast cancer. (2015)
- Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey (2015)
- Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu (2014)
- Frontal Lobe Like Syndrome Due To Bee Sting (2014)
- Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup (2014)
- Frontal Lobe Like Syndrome Due To Bee Sting (2014)
- Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up. (2013)
- MGMT VE TGASE-2 NİN RCC(RENAL HÜCRELİ KARSİNOM) HASTALARINDA PROGNOSTİK VE MRCC(METASTATİK RCC) HASTALARINDA SUNİTİNİB KULLANIMI İÇİN PREDİKTİF DEĞERİ (2013)
- Neoadjuvan kemoterapi alan lokal ileri meme kanserli hastalarda patolojik tam yanıtın değerlendirilmesi (2013)
- Multicentric Ipilimumab Experience in Turkish Patients with Metastatic Melanoma: MIPI-TURK at 3 years (2013)
- . MGMT(06-metilguanin-DNA metltransferaz) ve TGASE-2 (doku transglutaminaz-2) ‘in RCC Hastalarında Prognostik ve MRCC Hastalarında Sunitinib Kullanımı için Prediktif Değeri (2013)
- Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG) (2013)
- Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK. (2012)
- THE PREDICTIVE AND PROGNOSTIC ROLE OF O6-METHYLGUANINE- DNA METHYLTRANSFERASE (MGMT) AND TISSUE TRANSGLUTAMINASE-2 (TGASE-2) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH SUNITINIB (2012)